Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study

Meyer Antoine; Rudant Jeremie; Drouin Jerome; Weill Alain; Carbonnel Franck; Coste Joel

首页> 外文期刊>Annals of Internal Medicine >Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study

【24h】

Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study

机译：克罗恩病引基兴高采扣和生物仿生的有效性和安全性：法国等价研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: CT-P13 is a biosimilar of the reference product (RP) infliximab, with demonstrated efficacy and safety for some inflammatory arthritides. It was approved for the treatment of Crohn disease (CD) on that basis, without specific studies examining its effects in CD.

机译：背景：CT-P13是参考产物（RP）英夫利昔单抗的生物仿制物，具有一些炎性关节苷的疗效和安全性。它被批准在此基础上进行克罗恩病（CD），而无需检查其在CD中的作用。

著录项

来源
《Annals of Internal Medicine》 |2019年第2期|共22页
作者
Meyer Antoine; Rudant Jeremie; Drouin Jerome; Weill Alain; Carbonnel Franck; Coste Joel;
展开▼
作者单位

Caisse Natl Assurance Malad 50 Ave Prof Andre Lemierre F-75020 Paris France;

Caisse Natl Assurance Malad 50 Ave Prof Andre Lemierre F-75020 Paris France;

Caisse Natl Assurance Malad 50 Ave Prof Andre Lemierre F-75020 Paris France;

Caisse Natl Assurance Malad 50 Ave Prof Andre Lemierre F-75020 Paris France;

Hop Bicetre Serv Hepatogastroenterol Adulte 78 Rue Gen Leclerc F-94270 Le Kremlin Bicetre France;

Caisse Natl Assurance Malad 50 Ave Prof Andre Lemierre F-75020 Paris France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内科学;
关键词

相似文献

外文文献
中文文献
专利

1. Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study [J] . Meyer Antoine, Rudant Jeremie, Drouin Jerome, Annals of Internal Medicine . 2019,第2期

机译：克罗恩病引基兴高采扣和生物仿生的有效性和安全性：法国等价研究
2. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study [J] . Ye Byong Duk, Pesegova Marina, Alexeeva Olga, The Lancet . 2019,第10182期

机译：生物仿制性CT-P13的疗效和安全性与患有活跃的Crohn疾病患者的发起者英夫利昔单抗：国际，随机，双盲，第3期非劣级研究
3. Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study [J] . Cristina Vergara-Dangond, Marina Sáez Belló, Mónica Climente Martí, Drugs in R&D . 2017,第3期

机译：在炎症性风湿性疾病中从创新型英夫利昔单抗转用生物仿制药CT-P13的有效性和安全性：实际案例研究
4. Understanding Crohn's disease patients reaction to infliximab from facebook: A medical perspective [C] . M. Roccetti, P. Salomoni, C. Prandi, Proceedings of the 2016 IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining . 2016

机译：从facebook了解克罗恩病患者对英夫利昔单抗的反应：医学观点
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn’s Disease [O] . Avery Hughes, John K Marshall, Myla E Moretti, 2021

机译：与生物仿生素相比与克罗恩病患者维持参考英夫利昔单抗相比对生物仿生素的切换的成本实用性分析
7. DOP40 Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study [O] . A Meyer, J Rudant, J Drouin, 2019

机译：DOP40克罗恩疾病中引用的效果和安全性和生物素：法国等价研究

Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study

摘要

著录项

相似文献

相关主题

期刊订阅